• ABC

Trial Status

Closed

Cancer Type

Gallbladder & Biliary Tract

If you think this trial is relevant to your situation, please contact your Cancer Specialist to discuss further.

Protocol Title

A phase II trial of gemcitabine in fixed dose rate infusion combined with cisplatin in patients with inoperable biliary tract carcinomas.

Purpose of the Study

Biliary tract cancers are uncommon; as a result it is not a well-studied disease and treatment options for this condition are limited. This study will assess the impact of a new combination of chemotherapy drugs on the growth of the cancer and the undesirable side-effects of treatment.

Principal Invesitigator

Prof David Goldstein & Dr Jenny Shannon

More Information

Available online at the Australian New Zealand Clinical Trial Registry (ANZCTR), please click here.

Funding

Eli Lilly Australia P/L

Trial Status

Closed

Cancer Type

Gallbladder & Biliary Tract

If you think this clinical trial may be relevant to your patient or to discuss further, please contact the Clinical Trial team.

Protocol Title

AG0403BT

Conference Presentation Reference

  1. Australasian Gastrointestinal Trials Group; Shannon JA, Goldstein D, Brown C, Tebbutt N, Ackland S, Van Hazel G, Abdi E, Jefford M, Gainford MC, Jones-Murphy M. A phase II trial of gemcitabine in fixed dose rate infusion combined with low dose cisplatin in patients with inoperable biliary tract carcinomas. Gastrointestinal Cancers Symposium; 25–27 Jan 2008; Orlando. Abstract 243.
  2. Goldstein D, Shannon J, Brown C, Tebbutt N, Ackland S, Van Hazel G, Abdi E, Jefford M, Gainford MC, Adams K; for the Australasian Gastro-Intestinal Trials Group. ABC: an AGITG trial of fixed dose rate gemcitabine and cisplatin for patients with advanced biliary tract cancer. 43rd Annual Scientific Meeting of the American Society of Clinical Oncology; 1–5 Jun 2007; Chicago. Journal of Clinical Oncology 2007; 25 (18S, Part 1): 15015.

Aim

Biliary tract cancers are uncommon; as a result it is not a well-studied disease and treatment options for this condition are limited. This study will assess the impact of a new combination of chemotherapy drugs on the growth of the cancer and the undesirable side-effects of treatment.

Principal Investigator

Conjoint Professor David Goldstein, Medical Oncologist Prince of Wales Hospital NSW.
Doctor Jenny Shannon, Medical Oncologist Nepean Hospital NSW.

Funding

Eli Lilly Australia P/L